Font Size: a A A

Clinical Observation Of Zhaqu Jiangzhi Decoction In Treating Hyperlipidemia With Phlegm And Blood Stasis Syndrome

Posted on:2022-07-12Degree:MasterType:Thesis
Country:ChinaCandidate:X X LiFull Text:PDF
GTID:2504306521455344Subject:TCM
Abstract/Summary:PDF Full Text Request
Background At present,the prevalence of dyslipidemia in Chinese adults has increased significantly,and the prevention and control of Hyperlipidemia is in a serious situation.Hyperlipidemia is considered to be an important factor in the formation and development of atherosclerosis.It is closely related to a variety of cardiovascular and cerebrovascular diseases,and is an important independent risk factor for these diseases.Objective To observe the changes of blood lipid index(TC,TG,LDL,HDL),thrombosis risk(D-D,FIB),inflammatory factors(hs CRP,IL-6),TCM syndrome score and its improvement rate,carotid artery intima-media thickness(IMT)and plaque score in patients with hyperlipidemia of phlegm and blood stasis syndrome treated by zhaqu Jiangzhi Decoction.Objective to explore the efficacy,safety and possible mechanism of zhaqu Jiangzhi Decoction in the treatment of hyperlipidemia,and promote the development of this prescription in the clinical prevention and treatment of hyperlipidemia and cardiovascular and cerebrovascular diseases.Methods A total of 70 patients with hyperlipidemia diagnosed by western medicine and traditional Chinese medicine were randomly divided into observation group and control group,35 in each group.The control group was treated with atorvastatin calcium tablets,the observation group was treated with Zhaqu Jiangzhi Decoction combined with atorvastatin calcium tablets,and the decoction of traditional Chinese medicine was taken orally.The observation course of the two groups was 3 months.The changes of blood lipid(TC,TG,LDL,HDL),thrombus risk(D-D,FIB),inflammatory factors(hs-CRP,IL-6),TCM syndrome score and its improvement rate,carotid artery intima-media thickness(IMT)and plaque score,and the adverse reactions and safety of patients were evaluated.Finally,all data were analyzed by spss19.0 statistical software.Results There were no significant differences in age,gender,blood lipid index,thrombosis risk,inflammatory factors,TCM syndrome score,carotid intima-media thickness and plaque score between the two groups.The two groups were comparable(P>0.05).Analysis of lipid-lowering effect: TC,TG,LDL and HDL of the observation group and the control group were significantly improved after treatment(P<0.05);after treatment,the blood lipid index of the observation group was significantly different from that of the control group.(P<0.05)。Thrombus risk assessment,two groups after treatment D-D,FIB levels were significantly decreased,compared with before treatment,the difference was statistically significant(P<0.05);after treatment,the observation group D-D,FIB levels compared with the control group,decreased significantly(P<0.05).After treatment,the levels of inflammatory factors hs-CRP and IL-6 in the two groups were significantly decreased,and the difference was statistically significant(P<0.05);after treatment,the levels of hs CRP and IL-6 in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the TCM symptom scores of the two groups were significantly decreased compared with those before treatment(P<0.05);after treatment,the TCM symptom scores of the observation group were significantly improved compared with those of the control group(P<0.05).After treatment,the level of IMT in the observation group was significantly lower than that before treatment(P<0.05),and the plaque score was not significantly lower than that before treatment(P>0.05);the IMT in the control group was slightly lower than that before treatment,and the difference was not statistically significant(P>0.05,and there was no significant difference in the improvement of plaque score before treatment(P>0.05).There was no significant difference in safety and incidence of adverse reactions between the two groups(P>0.05).Conclusion(1)Zhaqu Jiangzhi Decoction combined with basic treatment can can reduce the risk of cardiovascular events by improving the levels of blood lipid,thrombosis risk and inflammatory factors in patients with hyperlipidemia of phlegm and blood stasis syndrome,and its curative effect is better than that of atorvastatin alone;(2)Compared with statins,Zhaqu Jiangzhi Decoction combined with basic treatment can significantly reduce the TCM syndrome score and improve the systemic symptoms of patients;(3)Zhaqu Jiangzhi Decoction combined with basic treatment can improve the carotid artery-media thickness,and delay the progress of plaque integral;(4)Zhaqu Jiangzhi Decoction combined with basic treatment has little effect on liver function and good clinical safety.
Keywords/Search Tags:Hyperlipidemia, Syndrome of phlegm and blood stasis, Thrombosis risk, Inflammatory factors, Zhaqu Jiangzhi Decoction
PDF Full Text Request
Related items